Industry Overview - The biotech and drug industry experienced a significant rebound in 2025 after a cautious start, driven by drug pricing agreements and increased M&A activity [1] - The FDA approved 44 novel therapies in 2025, with 26 approvals occurring in the second half of the year, indicating an acceleration in regulatory activity [1][2] Company Analysis: Altimmune (ALT) - Altimmune is focused on developing therapies for liver diseases, with its lead candidate pemvidutide currently in mid-stage studies for metabolic dysfunction-associated steatohepatitis (MASH) [4] - Shares of Altimmune have decreased over 46% year-to-date due to mixed results from the phase IIb IMPACT study, although it met one primary endpoint related to MASH resolution [5] - Recent 48-week results from the IMPACT study showed further improvements in non-invasive tests and significant reductions in liver health biomarkers [6] - Altimmune plans to initiate a late-stage study for pemvidutide in MASH in 2026 after aligning with the FDA on key parameters [7] - The company is also exploring pemvidutide for alcohol use disorder and alcohol-associated liver disease, with data expected next year [8] Company Analysis: ImmunityBio (IBRX) - ImmunityBio focuses on therapies for cancer and infectious diseases, with its marketed drug Anktiva approved for bladder cancer [11] - Shares of ImmunityBio have declined over 16% this year due to a regulatory setback from the FDA regarding a label expansion for Anktiva [12] - Despite the setback, Anktiva generated nearly $75 million in sales this year, a significant increase from $7 million in the previous year, and the company is seeking EU market expansion [13] - ImmunityBio is also developing Anktiva for other cancer indications, with promising data in non-small cell lung cancer and glioblastoma expected to be updated in 2026 [14] - Loss per share estimates for 2026 have improved from $0.37 to $0.33 in the past 60 days [15] Company Analysis: Seres Therapeutics (MCRB) - Seres Therapeutics is developing SER-155, an oral live biotherapeutic aimed at preventing bloodstream infections in patients undergoing stem cell transplantation [16] - Investor interest in SER-155 increased after a phase Ib study showed a 77% relative reduction in bacterial infections compared to placebo [17] - The FDA has provided positive feedback for SER-155's advancement to mid-stage development, with an interim update expected within 12 months of study initiation [18] - Shares of Seres Therapeutics have decreased nearly 12% year-to-date, but loss per share estimates for 2026 have improved from $10.66 to $7.67 in the past 60 days [18]

Company Overview - Seres Therapeutics, Inc. (Nasdaq: MCRB) is a clinical-stage company focused on improving patient outcomes in medically vulnerable populations through novel live biotherapeutics [4] - The company successfully developed and approved VOWST™, the first FDA-approved orally administered microbiome therapeutic, which was sold to Nestlé Health Science in September 2024 [4] - Seres is developing SER-155, which has received Breakthrough Therapy designation for reducing bloodstream infections in adults undergoing allo-HSCT and Fast Track designation for reducing the risk of infection and graft-versus-host disease in the same patient population [4] Clinical Developments - SER-155 has demonstrated a significant reduction in bloodstream infections and related complications compared to placebo in a Phase 1b clinical study involving patients undergoing allo-HSCT [4] - The company plans to evaluate SER-155 and other cultivated live biotherapeutic candidates in various medically vulnerable patient populations, including autologous-HSCT patients, cancer patients with neutropenia, CAR-T recipients, individuals with chronic liver disease, solid organ transplant recipients, and patients in intensive care units and long-term acute care facilities [4] Upcoming Events - Management will host a conference call and live audio webcast on May 7, 2025, at 8:30 a.m. ET to discuss first quarter 2025 financial results and provide business updates [1] - Access to the conference call can be made by dialing 800-715-9871 (domestic) or 646-307-1963 (international) with conference ID number 4618787 [2] - A webcast replay will be available on the Seres website approximately two hours after the event and will be archived for about 21 days [3]

Core Viewpoint - Seres Therapeutics (MCRB) has experienced a significant decline of 48.7% over the past four weeks, but it is now positioned for a potential trend reversal as it enters oversold territory, with analysts predicting better earnings than previously expected [1]. Group 1: Stock Performance and Technical Indicators - MCRB's stock has been under heavy selling pressure, leading to an RSI reading of 29.27, indicating it is nearing oversold conditions [5]. - The Relative Strength Index (RSI) is a momentum oscillator that helps identify whether a stock is oversold, typically when the RSI falls below 30 [2][3]. Group 2: Earnings Estimates and Analyst Consensus - There is strong consensus among sell-side analysts that MCRB will report improved earnings, with the consensus EPS estimate increasing by 8.6% over the last 30 days [7]. - MCRB holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, indicating a favorable outlook for a turnaround [8].

Core Insights - Seres Therapeutics is advancing SER-155, a live biotherapeutic candidate aimed at preventing bloodstream infections in patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT), with a significant 77% relative risk reduction in bloodstream infections reported in Phase 1b studies [3][4][14] - The FDA has granted SER-155 Breakthrough Therapy designation, facilitating expedited development and communication with the agency [4][14] - The company plans to submit a draft study protocol for the next phase of SER-155 to the FDA in Q2 2025, with potential study designs being either a standalone Phase 2 or a Phase 2/3 seamless design [3][6] Financial Performance - For the full year 2024, Seres reported a net loss from continuing operations of $125.8 million, an improvement from a net loss of $190.1 million in 2023 [10][24] - Research and development expenses decreased to $64.6 million in 2024 from $117.6 million in 2023, reflecting a strategic focus on SER-155 [10][24] - The company had $30.8 million in cash and cash equivalents as of December 31, 2024, and expects to fund operations into Q1 2026 based on current cash and anticipated payments from Nestlé [11][10] Strategic Developments - Seres is in discussions for strategic partnerships to accelerate the development of SER-155 and explore its application in other high-risk patient populations [3][6] - The company has identified significant market opportunities for SER-155, with an estimated 9,300 allo-HSCT procedures conducted annually in the US and approximately 20,000 in Europe [6][10] - The recent exploratory biomarker data from the Phase 1b study supports the therapeutic mechanisms of SER-155 and its potential to address inflammatory and immune diseases [6][10] Corporate Updates - In September 2024, Seres sold its VOWST business to Nestlé for approximately $175 million, which included an upfront payment and future milestone payments based on sales [5][7] - The company appointed Dr. Hans-Juergen Woerle as a director, fulfilling rights granted to Nestlé as part of their investment in Seres [7] - Seres plans to present SER-155 data at upcoming medical meetings to engage with potential European investigators [10]

Core Insights - The FDA has provided constructive feedback on Seres Therapeutics' SER-155 development plans, supporting a Phase 2 study with a primary efficacy endpoint focused on reducing bloodstream infections (BSIs) post-allo-HSCT [1][2][4] - Seres Therapeutics plans to submit a proposed protocol for the next SER-155 study to the FDA in Q2 2025, incorporating the agency's feedback [1][2] - SER-155 has shown a 77% relative risk reduction in BSIs in a Phase 1b study, along with reduced systemic antibiotic exposure and lower incidence of febrile neutropenia [2][4] Company Overview - Seres Therapeutics, Inc. is a clinical-stage company focused on live biotherapeutics aimed at improving outcomes for medically vulnerable populations [5] - The company has received Breakthrough Therapy designation for SER-155, targeting the reduction of BSIs in allo-HSCT patients, and Fast Track designation for reducing infection risk and graft-versus-host disease [5][4] - SER-155 is designed to decolonize gastrointestinal pathogens and improve immune tolerance in patients undergoing allo-HSCT for hematological malignancies [3][5] Future Development Plans - The next study design for SER-155 may retain elements from the previous Phase 1b trial, which demonstrated significant clinical benefits [2][4] - The company is actively seeking partnerships to support the further development of SER-155 in allo-HSCT [2]